We first backed Neuronostics when we led their seed round in 2024. Today we are delighted to celebrate the next chapter: a £3M raise, co-led by Empirical Ventures and The FSE Group, with Ascension continuing to back the team alongside British Business Bank's South West Investment Fund, QantX, New Wave Venture Partners and Angel Investors Bristol. The round is complemented by a £400k Innovate UK Investor Partnerships grant.
Neuronostics is tackling one of the hardest problems in neurology: diagnosing epilepsy. Patients can wait more than a year for a definitive answer. Its BioEP platform applies digital biomarkers to routine EEG recordings, detecting epilepsy-associated features even when traditional epileptiform activity is absent, and giving clinicians a faster, more confident diagnosis.
The new funding will support an FDA submission planned for 2026, broader NHS adoption of BioEP, and development of the platform to measure treatment response in pharmaceutical trials.
Congratulations to the whole Neuronostics team. We are proud to keep backing them.